The FDA's Center for Biologics Evaluation and Research issued draft guidance on April 14 titled "Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing," Docket FDA-2026-D-1255, with the comment window running through July 14. [1] Tuesday is Day 7 of that window. The paper's Monday Day-One brief opened the clock at the release date; the April 15 Federal Register publication formalized it. [2]

The guidance is an extension, not a new framework. It builds on the January 2024 CBER guidance on human gene therapy products incorporating human genome editing — the plausible-mechanism foundation the paper's February coverage tracked — and adds explicit recommendations for how sponsors should design NGS-based nonclinical studies to assess off-target editing, unintended insertions, and chromosomal translocations before filing an Investigational New Drug application. [3] For CRISPR, base editors, and prime editors that cause DNA double-strand breaks or medium-to-large insertions, the document recommends genome-wide NGS methods capable of detecting low-frequency translocation events.

The comment window matters more than the draft. Industry groups — the Alliance for Regenerative Medicine, BIO, and academic consortia — are expected to push on sequencing-depth thresholds and the proposed one-cell-per-colony confirmation step. The paper's reading of Day 7: no public comments have yet been filed to the docket, and none of the expected academic laboratories has issued position papers. The policy-calendar shape is set. What sponsors write to regulations.gov over the next ninety-three days is the test.

-- KENJI NAKAMURA, Tokyo